Advertisement
New Zealand markets close in 12 minutes
  • NZX 50

    11,763.81
    -19.58 (-0.17%)
     
  • NZD/USD

    0.6133
    +0.0010 (+0.17%)
     
  • NZD/EUR

    0.5650
    +0.0012 (+0.22%)
     
  • ALL ORDS

    8,059.70
    +60.50 (+0.76%)
     
  • ASX 200

    7,790.40
    +62.80 (+0.81%)
     
  • OIL

    78.00
    +0.28 (+0.36%)
     
  • GOLD

    2,343.50
    +9.00 (+0.39%)
     
  • NASDAQ

    18,808.35
    +184.95 (+0.99%)
     
  • FTSE

    8,317.59
    -21.64 (-0.26%)
     
  • Dow Jones

    39,069.59
    +4.29 (+0.01%)
     
  • DAX

    18,693.37
    +2.07 (+0.01%)
     
  • Hang Seng

    18,665.79
    +56.85 (+0.31%)
     
  • NIKKEI 225

    38,720.60
    +74.49 (+0.19%)
     
  • NZD/JPY

    96.0870
    +0.0010 (+0.00%)
     

Cross Country Healthcare First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Cross Country Healthcare (NASDAQ:CCRN) First Quarter 2024 Results

Key Financial Results

  • Revenue: US$379.2m (down 39% from 1Q 2023).

  • Net income: US$2.69m (down 91% from 1Q 2023).

  • Profit margin: 0.7% (down from 4.7% in 1Q 2023). The decrease in margin was driven by lower revenue.

  • EPS: US$0.079 (down from US$0.82 in 1Q 2023).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Cross Country Healthcare Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) missed analyst estimates by 51%.

Looking ahead, revenue is expected to decline by 6.7% p.a. on average during the next 3 years, while revenues in the Healthcare industry in the US are expected to grow by 6.7%.

ADVERTISEMENT

Performance of the American Healthcare industry.

The company's shares are down 2.3% from a week ago.

Risk Analysis

It is worth noting though that we have found 3 warning signs for Cross Country Healthcare (1 shouldn't be ignored!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.